EIF4EBP1 and prostate carcinoma: More recently, in patients with prostate cancer treated with metformin between the day of prognosis and the radical prostatectomy, Joshua et al.76 have observed a reduction in Ki67 staining and a significant decrease in the phosphorylation of P-4EBP1, a target of mTORC1.